research The promise and challenges of cell therapy for psoriasis*
Cell therapy shows promise for treating severe psoriasis but needs more research to confirm safety and effectiveness.
Search
for
Sort by
Research
360-390 / 1000+ results 
research In reply
Combining pulsed prednisone with tofacitinib can lead to lasting hair regrowth in severe alopecia areata patients.
research The Shifting Landscape of Disease-Modifying Therapies for Relapsing Multiple Sclerosis
New treatments for relapsing multiple sclerosis are more effective and convenient but have higher risks of serious side effects.
research Plasma proteome–driven identification of druggable immune regulators of alopecia areata, validated by transcriptome and single-cell mapping
Belatacept may be a promising treatment for alopecia areata.
research Cytokine-Targeting Biologic Therapies for Alopecia Areata: A Comprehensive Review of Mechanism of Action, Clinical Efficacy, and Adverse Events
Dupilumab and ustekinumab are promising treatments for alopecia areata, showing significant hair regrowth.
research 0009 Regulatory γδ T cells protect human scalp hair follicles from alopecia areata in vivo and represent potential therapeutic target
γδ T cells can prevent and treat alopecia areata, offering a new therapy option.
research Innate immunity and the regulation and mobilization of keratinocyte stem cells: are the old players playing a new game?
Innate immunity genes in hair follicle stem cells might have new roles beyond traditional immune functions.
research Learning From Success and Failure: Biologics for Non-approved Skin Diseases
Biologics show promise in treating various stubborn skin diseases, but more research and better reimbursement criteria are needed.
research Il-10 family members as novel responders to genotoxic stress
IL-19 and IL-24 help cells respond to DNA damage and could be targeted for cancer and age-related disease treatments.
research PC-SPES Studies Promising, But Manufacturer Shuts Down
Promising cancer treatments were found, but the manufacturer closed.
research ANTI-CD19 MONOCLONAL ANTIBODY FOR SYSTEMIC LUPUS ERYTHEMATOSUS AND NEUROMYELITIS OPTICA SPECTRUM DISORDER
Anti-CD19 therapy may help treat SLE and NMOSD.
research The vitamin B5/coenzyme A axis: A target for immunomodulation?
Vitamin B5 and coenzyme A may help regulate the immune system and could improve treatments for chronic diseases and cancer.
research <p>The regenerative potential of skin and the immune system</p>
The skin's immune system helps it regenerate and fight infections.
research Nanoparticle Adjuvants Incorporating Haptens Drive Potent Immune Tolerance to Accelerate Hair Regrowth
Nanoparticles with specific drugs can help regrow hair in alopecia areata.
research Combined Low Dose Oral Minoxidil and Immunomodulator Efficacy and Safety in Alopecia Areata: A Systematic Review
Combining low-dose oral minoxidil with immunomodulators shows promise for treating alopecia areata but needs more research.
research New and Emerging Therapies for Alopecia Areata
Emerging therapies like JAK inhibitors show promise for hair regrowth in alopecia areata.
research Exploring Mast Cell–CD8 T Cell Interactions in Inflammatory Skin Diseases
Mast cells and CD8 T cells interact closely in skin diseases, affecting each other's behavior and contributing to conditions like psoriasis and eczema.
research The role of skin macrophages under conditions of stress and injury: ultraviolet irradiation and wound healing
Inhibiting IL-17 and IL-23 improves wound healing in obese, diabetic mice by promoting healing macrophages.
research Nano-pulse stimulation™ therapy (NPS™) is superior to cryoablation in clearing murine melanoma tumors
Nano-Pulse Stimulation™ Therapy is more effective and less damaging than cryoablation for treating melanoma tumors in mice.
research 544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1)
Oral JAK inhibitors improved alopecia areata by modulating immune responses and boosting hair growth.
research The immunopathogenesis of Alopecia Areata
Alopecia areata is an autoimmune disease causing hair loss, and targeting macrophages may help treat it.
research Alopecia areata: Time for position statement to include new systemic therapeutic advances
New treatments for severe alopecia areata, especially JAK inhibitors, are recommended as first-line therapy.
research 700 Oncostatin M is upstream of JAK-STAT signaling during the murine hair cycle
Blocking Oncostatin M's role in the JAK-STAT pathway can stimulate hair growth in mice.
research Dormant tumor cells in ret transgenic mouse melanoma model and their interaction with memory T cells
Dormant melanoma cells in mice interact minimally with memory T cells due to a suppressive tumor environment.
research Selective Expression of Chemokine Monokine Induced by Interferon-γ in Alopecia Areata
Targeting MIG and MCP-1 may help treat inflammation in alopecia areata.
research Regulatory T-Cells: Potential Regulator of Tissue Repair and Regeneration
Regulatory T-cells are important for healing and regenerating tissues in various organs by controlling immune responses and aiding stem cells.
research Stepwise acquisition of unique epigenetic signatures during differentiation of tissue Treg cells
Tissue environment greatly affects the unique epigenetic makeup of regulatory T cells, which could impact autoimmune disease treatment.
research JAK-inhibitors in the therapy of comorbid diseases – atopic dermatitis and alopecia areata: literature review and experience of clinical practice
JAK inhibitors effectively treat severe atopic dermatitis and alopecia areata.
research Tumour regression predicts higher risk of sentinel node involvement in thin cutaneous melanomas
Shrinking skin cancer increases the chance of cancer in nearby lymph nodes.
research Drugs targeting the JAK/STAT pathway for the treatment of immune-mediated inflammatory skin diseases: protocol for a scoping review
JAK/STAT inhibitors show promise for skin diseases but aren't yet approved.